secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001104659-22-087924
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaccitech reports Q2 net income of $15.7M on $17.1M in Vaxzevria royalties
--------------------------------------------------------------------------

- Net income $15.7M ($0.41 diluted EPS) vs $2.6M ($0.068) in Q1 2022.
- Revenue $17.1M from milestone/royalty payments from AstraZeneca for Vaxzevria sales.
- Cash $192.3M at June 30 vs $214.1M at Dec 31, 2021; $15.0M used in operations.
- R&D expenses $9.7M (down from $10.7M); G&A excluding FX gain was $8.8M.
- Clinical highlights: VTP-300 HBV data, EMA advice for MERS vaccine, HPV trial enrollment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000110465922087924/0001104659-22-087924-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000110465922087924/tm2222823d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-087924

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer